key: cord-0804513-dzq0yzev
authors: Aslam, Saima; Ison, Michael G.
title: SARS-CoV-2 Vaccination in Heart Transplantation: What We Do and Do Not Know
date: 2021-11-04
journal: J Heart Lung Transplant
DOI: 10.1016/j.healun.2021.10.017
sha: 8c6feec61eb774ab0e89a76c516e5703a777f982
doc_id: 804513
cord_uid: dzq0yzev

nan

Vaccination is a key component in our armamentarium against coronavirus disease 2019 (COVID-19) and, in particular, for preventing severe illness and death from this infection. Unfortunately, but not surprisingly, solid organ transplant recipients (SOTR) mount a less robust antibody response, and to a lesser degree, cellular response to vaccines.(1) It is therefore not surprising that heart transplant (HT) recipients experience lower rates of seroconversion following COVID-19 vaccination. In general, detectable antibodies against the receptor-binding domain of the spike protein of the SARS-CoV-2 virus are demonstrated in 10-57% and cellular response in 10-70% of HT recipients following two doses of mRNA vaccines.(2-6) Increased intensity of immunosuppression, use of anti-metabolites such as mycophenolate, and agents that inhibit B-cell response are associated with reduced immunogenicity. Other factors include older age, use of belatacept, lower total lymphocyte count, lower estimated glomerular filtration and hypogammaglobulinemia.(4, 6, 7) Despite sub-optimal seroconversion rates, vaccination was associated with reduced risk of death from COVID-19 in a national United Kingdom registry (8) as well as 80% reduced risk of symptomatic disease in a single center cohort, when compared to unvaccinated SOTR. (9) Third dose mRNA vaccination in SOTR is associated with an increase in detectable humoral response ranging from 55-67.9%.(7, 10-12) However, specific HT data in this setting has been sparse as previous studies included only 28 HT patients and HTspecific results were not reported. (10) (11) (12) Additionally, safety of third doses in HT recipients is not clear. A case of biopsy-proven acute antibody mediated rejection in a HT recipient was reported and occurred 7 days following a third vaccine dose. (12) Myocarditis is a rare complication and estimated to occur in 12.6 cases per million doses of second-dose mRNA vaccine among individuals between 12-39 years of age with a male predominance. Most confirmed vaccine-related myocarditis cases are mild, occur within 7 days of vaccination, and associated with complete resolution. (13) Vaccine-related myocarditis in HT recipients has not been described.

The study by Peled et al is the first to systematically assess the safety and immunogenicity of a third dose mRNA vaccine administered approximately 6 months following the second in HT recipients. The authors report an acceptable safety profile in 96 adult HT patients with no reported serious adverse events or episodes of rejection within a month of follow-up from the third dose. At 18 days following the third vaccine dose, detectable antibody response increased from 23% to 67%; SARS-CoV-2 neutralization titers also increased significantly. In this study, mycophenolate use, poor kidney function, and elevated C-reactive protein levels were independently associated with a reduced likelihood of generating an immune response. A subset of 15 patients underwent assessment of specific T-cell response, which was present in 80% after the 3 rd dose. In this study, as in others, cellular responses were evident in the absence of measurable antibodies, suggesting benefit, even when there did not appear to be an antibody response. (4) As we start administering third dose mRNA vaccines to SOTR and other patient populations, much of the world that received non-mRNA vaccines is left behind. Current data from Europe demonstrates superior immunogenicity (both humoral and cellular responses) with a heterologous prime/boost strategy for the ChAdOx1 vaccine (Oxford-AstraZeneca) followed by mRNA vaccines BNT162b2 (Pfizer) and/ or mRNA1273 (Moderna) compared to homologous strategy of two doses of ChAdOx1 (14-16) in otherwise healthy patients; one study noted superiority of this regimen to two doses of mRNA vaccine as well though not seen in others. (15) Similarly, heterologous boosting with mRNA vaccine after vector priming led to significantly increased antibody and Cd4

T-cell response in SOTR in a recent study. (17) Specific data on which approach to boosting SOTR who received non-mRNA vaccines is minimal and use of booster doses in these patients is ideally performed as part of a research study to inform best practices. Developing these data are essential to allow boosting with the optimal strategy for all patients who may need additional doses of vaccine. To summarize, COVID-19 vaccination is generally safe and well tolerated in SOTR, including HT recipients. Additional vaccine doses are now recommended for SOTRs in some countries who have received mRNA SARS-CoV-2 vaccines due to less effective humoral and cellular responses following the original dosing strategies. We believe that while we work on optimizing immunogenicity in vaccinated SOTR, we also need to devote time and energy in outreach efforts to increased vaccination rates overall as well as alternative strategies to effectively protect our patients from COVID-19. While significant attention has been paid to boosters for our SOTRs, large numbers of our patients remain unvaccinated.

Serologic vaccination response after solid organ transplantation: a systematic review

Antibody Response to 2-Dose SARS-CoV-2 mRNA Vaccine Series in Solid Organ Transplant Recipients

BNT162b2 vaccination in heart transplant recipients: clinical experience and antibody response

Cellular and humoral immune response after mRNA-1273 SARS-CoV-2 vaccine in liver and heart transplant recipients

Poor humoral and T-cell response to two-dose SARS-CoV-2 messenger RNA vaccine BNT162b2 in cardiothoracic transplant recipients

Immunogenicity of the

BNT162b2 mRNA vaccine in heart transplant recipients -a prospective cohort study

Efficiency of a boost with a third dose of anti-SARS-CoV-2 messenger RNA-based vaccines in solid organ transplant recipients

Two Doses of SARS-CoV

Vaccines Reduce Risk of Death Due to COVID-19 in Solid Organ Transplant Recipients: Preliminary Outcomes From a UK Registry Linkage Analysis

vaccination in solid organ transplant recipients

Randomized Trial of a Third Dose of mRNA-1273 Vaccine in Transplant Recipients

A: Three Doses of an mRNA Covid-19 Vaccine in Solid-Organ Transplant Recipients

Safety and Immunogenicity of a Third Dose of SARS-CoV-2 Vaccine in Solid Organ Transplant Recipients: A Case Series

Myocarditis With COVID-19 mRNA Vaccines

Immune responses against SARS-CoV-2 variants after heterologous and homologous ChAdOx1 nCoV-19/BNT162b2 vaccination

Immunogenicity and reactogenicity of heterologous ChAdOx1 nCoV-19/mRNA vaccination

Safety and immunogenicity of heterologous versus homologous prime-boost schedules with an adenoviral vectored and mRNA COVID-19 vaccine (Com-COV): a single-blind, randomised, non-inferiority trial

Cellular immunity predominates over humoral immunity after homologous and heterologous mRNA and vector-based COVID-19 vaccine regimens in solid organ transplant recipients

Safety and Cross-Variant Immunogenicity of a Three-dose COVID-19 mRNA Vaccine